AdipoPharma key facts
- Developer of a peptide-based drug designed to offer treatment for patients suffering from type 2 diabetes.
- AdipoPharma’s last known valuation is $18.4M.
- It has raised $34.5M; the latest was Later Stage VC ($9.4M) in Nov 2024.
- Notable investors include Bpifrance, Morningside Group, Good Growth Capital, Okeanos (United States), SambrInvest — 11 tracked in total.
- Status: Privately Held (backing).
Who backs AdipoPharma
11+- ·The complete investor list: 11 names
- ·Watch AdipoPharma: the Monday email on marks, rounds and moves
AdipoPharma funding rounds
No funding rounds for AdipoPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AdipoPharma valuation
AdipoPharma's last known valuation is $18.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
AdipoPharma investors
11 investors are on record for AdipoPharma, including Bpifrance, Morningside Group, Good Growth Capital and Okeanos (United States).
About AdipoPharma
Developer of a peptide-based drug designed to offer treatment for patients suffering from type 2 diabetes. The company's drugs undergo a detailed analysis of the adipocyte's complex function, its intrinsic lipid modulating effects, and a targeted approach to treatment, enabling patients to restore healthy lipid biosynthesis in the diseased adipocyte and have a beneficial effect on insulin resistance as well as insulin sensitivity, beta-cell plaque removal, liver steatosis, and fibrosis.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2017
- Employees
- 6
- Website
- adipopharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AdipoPharma’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.